Cell metabolism · 2021
Pharmacological inhibition of arachidonate 12-lipoxygenase ameliorates myocardial ischemia-reperfusion injury in multiple species.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Xiao-Jing, Liu Xiaolan, Hu Manli, Zhao Guo-Jun, Sun Dating, Cheng Xu, Xiang Hui, Huang Yong-Ping, Tian Rui-Feng, Shen Li-Jun, Ma Jun-Peng, Wang Hai-Ping, Tian Song, Gan Shanyu, Xu Haibo, Liao Rufang, Zou Toujun, Ji Yan-Xiao, Zhang Peng, Cai Jingjing, Wang Zhao V, Meng Guannan, Xu Qingbo, Wang Yibin, Ma Xin-Liang, Liu Peter P, Huang Zan, Zhu Lihua, She Zhi-Gang, Zhang Xin, Bai Lan, Yang Hailong, Lu Zhibing, Li Hongliang
Аннотация
Myocardial ischemia-reperfusion (MIR) injury is a major cause of adverse outcomes of revascularization after myocardial infarction. To identify the fundamental regulator of reperfusion injury, we performed metabolomics profiling in plasma of individuals before and after revascularization and identified a marked accumulation of arachidonate 12-lipoxygenase (ALOX12)-dependent 12-HETE following revascularization. The potent induction of 12-HETE proceeded by reperfusion was conserved in post-MIR in mice, pigs, and monkeys. While genetic inhibition of Alox12 protected mouse hearts from reperfusion injury and remodeling, Alox12 overexpression exacerbated MIR injury. Remarkably, pharmacological inhibition of ALOX12 significantly reduced cardiac injury in mice, pigs, and monkeys. Unexpectedly, ALOX12 promotes cardiomyocyte injury beyond its enzymatic activity and production of 12-HETE but also by its suppression of AMPK activity via a direct interaction with its upstream kinase TAK1. Taken together, our study demonstrates that ALOX12 is a novel AMPK upstream regulator in the post-MIR heart and that it represents a conserved therapeutic target for the treatment of myocardial reperfusion injury.